Bone Biologics Corporation
BBLG
$0.55
-$0.01-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 499.40K | 663.50K | 475.90K | 527.50K | 556.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 808.10K | 805.10K | 733.10K | 715.30K | 748.10K |
| Operating Income | -808.10K | -805.10K | -733.10K | -715.30K | -748.10K |
| Income Before Tax | -773.70K | -766.00K | -684.60K | -666.70K | -740.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -773.70K | -766.00K | -684.60K | -666.70K | -740.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -773.70K | -766.00K | -684.60K | -666.70K | -740.50K |
| EBIT | -808.10K | -805.10K | -733.10K | -715.30K | -748.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.43 | -0.43 | -0.38 | -0.37 | -1.33 |
| Normalized Basic EPS | -0.27 | -0.27 | -0.24 | -0.23 | -0.83 |
| EPS Diluted | -0.43 | -0.43 | -0.38 | -0.37 | -1.33 |
| Normalized Diluted EPS | -0.27 | -0.27 | -0.24 | -0.23 | -0.83 |
| Average Basic Shares Outstanding | 1.80M | 1.80M | 1.80M | 1.80M | 557.80K |
| Average Diluted Shares Outstanding | 1.80M | 1.80M | 1.80M | 1.80M | 557.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |